Servier Servier, Celsius Therapeutics Partner to Identify Colorectal Cancer Drug Targets Servier will have an exclusive option to research, develop, and commercialize products for up to three of the targets identified by Celsius. Saga, Servier Sign Liquid Biopsy Services Deal Saga has developed a digital PCR-based technology that it says can detect circulating tumor DNA with a mutational allele frequency of 0.001 percent. European Consortium Aims to Deliver New Tests, Therapies for Cardiovascular Diseases Premium Backed by €19 million in EU funding, the initiative, called [email protected], will create a research platform that could change the way cardiovascular diseases are diagnosed and treated. Miragen, Servier Extend microRNA Drug Alliance Premium NEW YORK (GenomeWeb) – Miragen Therapeutics this week announced that its research and development collaboration with France's Servier has been extended by two years to October 2016. Institut-Curie, Servier Extend Triple-negative Breast Cancer Partnership NEW YORK (GenomeWeb News) — Curie-Cancer, which leads Institut Curie's industry partnerships, and the French drug developer Servier have extended an ongoing partnership focused on breast cancer research for another three years, they said today. May 23, 2013 MiRagen Hits First Milestone in Servier microRNA Drug Partnership Premium Mar 13, 2013 France Funds $17M Cancer Profiling, Biomarker Effort Nov 8, 2011 Servier, Prognomix Agree to ID Targets for Diabetes, Metabolic Disease Treatments Oct 21, 2011 Hybrigenics' H1 Revenue Down 2 Percent, But Proteomics Services Up 8 Percent Premium Oct 20, 2011 Miragen Seals microRNA Drug Partnership with Servier Worth Up to $1B Premium Oct 10, 2011 Hybrigenics, Servier Partner on Deal for Rx, Companion Dx Development Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.